



Challenges in Cancer-Associated Thrombosis

Guest Editor:

Dr. Remedios Otero-Candelera

1. Medical Surgical Unit of Respiratory Diseases, Hospital Universitario Virgen del Rocío, Seville, Spain
2. Instituto de Biomedicina de Sevilla (IBIS)/CSIC/Universidad de Sevilla, CIBERES, Spain

Deadline for manuscript submissions:

closed (31 May 2022)

Message from the Guest Editor

Cancer patients are at increased risk of venous thromboembolism (VTE). VTE incidence associated with cancer has increased due to VTE detection in routine-imaging testing for cancer staging. VTE in cancer presents an increased risk of recurrence, bleeding, and mortality. The updated guidelines recommend either apixaban, rivaroxaban, or low molecular weight heparin (LMWH) for thromboprophylaxis in selected high-risk outpatients with cancer without a contraindication to anticoagulation or drug–drug interactions. Guidelines also consider rivaroxaban, edoxaban or LMWH as options for the treatment of VTE in cancer patients. LMWH, edoxaban, and rivaroxaban are preferred for long-term anticoagulation (at least 6 months). It is considered anticoagulation beyond 6 months in select patients with metastatic disease or those receiving chemotherapy, but biomarkers that guide us on the duration of VTE treatment in cancer patients are not yet established.

In this Special Issue, articles about direct oral anticoagulant drugs in cancer patients and about different approaches to select cancer patients for thromboprophylaxis or to decide the suitable anticoagulation duration will be reported.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)